375 related articles for article (PubMed ID: 33639890)
21. Systemic light chain amyloidosis myopathy responsive to daratumumab monotherapy.
Chitimus DM; Berling E; Garderet L; Venturelli N; Malfatti E; Authier FJ; Nicolas G; Laforêt P; Lefeuvre C
Eur J Neurol; 2023 Mar; 30(3):745-748. PubMed ID: 36403110
[TBL] [Abstract][Full Text] [Related]
22. Rate and Predictors of Finding Monoclonal Gammopathy of Renal Significance (MGRS) Lesions on Kidney Biopsy in Patients with Monoclonal Gammopathy.
Klomjit N; Leung N; Fervenza F; Sethi S; Zand L
J Am Soc Nephrol; 2020 Oct; 31(10):2400-2411. PubMed ID: 32747354
[TBL] [Abstract][Full Text] [Related]
23. [Monoclonal gammapathy of renal significance (MGRS) at the current state: terminology, diagnosis and treatment].
Lysenko Kozlovskaya LV; Rameev VV; Androsova TV
Ter Arkh; 2020 Jul; 92(6):15-22. PubMed ID: 33346488
[TBL] [Abstract][Full Text] [Related]
24. Axial myopathy due to primary amyloidosis.
Friedman Y; Paul JT; Turley J; Hazrati LN; Munoz D
Muscle Nerve; 2007 Oct; 36(4):542-6. PubMed ID: 17405139
[TBL] [Abstract][Full Text] [Related]
25. A unique case of light chain (AL) amyloidosis masquerading as hypophosphatemic osteomalacia.
Malhotra R; Guleria P; Barwad A; Pramanik R; Tandon N
Osteoporos Int; 2021 Feb; 32(2):387-392. PubMed ID: 32910218
[TBL] [Abstract][Full Text] [Related]
26. Lambda light chain-induced monoclonal gammopathy of renal significance, manifesting with Fanconi Syndrome and osteomalacia.
Gutiérrez-Peredo GB; Filho JCBO; Montaño-Castellón I; Gutiérrez-Peredo AJ; Crusoé EQ; Gusmao-Flores D
BMC Nephrol; 2022 Aug; 23(1):278. PubMed ID: 35945525
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors.
Gozzetti A; Guarnieri A; Zamagni E; Zakharova E; Coriu D; Bittrich M; Pika T; Tovar N; Schutz N; Ciofini S; Peña C; Rocchi S; Rassner M; Avivi I; Waszczuk-Gajda A; Chhabra S; Usnarska-Zubkiewicz L; González-Calle V; Mateos MV; Bocchia M; Bigi F; Füllgraf H; Bhasin-Chhabra B; Gentile M; Davila J; Vesole DH; Cavo M; Thapa B; Crusoe E; Einsele H; Legiec W; Charliński G; Jurczyszyn A
Am J Hematol; 2022 Jul; 97(7):877-884. PubMed ID: 35389534
[TBL] [Abstract][Full Text] [Related]
28. Inflammatory features in sporadic late-onset nemaline myopathy are independent from monoclonal gammopathy.
Tanboon J; Uruha A; Arahata Y; Dittmayer C; Schweizer L; Goebel HH; Nishino I; Stenzel W
Brain Pathol; 2021 May; 31(3):e12962. PubMed ID: 34043258
[TBL] [Abstract][Full Text] [Related]
29. Updates in Plasma Cell Dyscrasias and Related Monoclonal Immunoglobulin-Mediated Renal Disease.
Midha S; Nadeem O; Selamet U
Semin Nephrol; 2022 Nov; 42(6):151352. PubMed ID: 37257390
[TBL] [Abstract][Full Text] [Related]
30. AL amyloidosis with IgD-lambda monoclonal gammopathy and lambda-type Bence-Jones protein: successful treatment by autologous stem cell transplantation.
Sakurai-Chin C; Ubara Y; Suwabe T; Hoshino J; Yonaha T; Hasegawa E; Sumida K; Hiramatsu R; Yamanouchi M; Hayami N; Yamauchi J; Tominaga N; Sawa N; Takemoto F; Masuoka K; Takaichi K; Oohashi K
Clin Exp Nephrol; 2010 Oct; 14(5):506-10. PubMed ID: 20632063
[TBL] [Abstract][Full Text] [Related]
31. [A systemic disease mimicking a rheumatoid arthritis].
Legrand M; Nouvier M; Paulin L; Deschamps B; Pialat JB; Coury F
Rev Med Interne; 2019 Dec; 40(12):831-836. PubMed ID: 31444022
[TBL] [Abstract][Full Text] [Related]
32. Monoclonal gammopathy of renal significance (MGRS): the characteristics and significance of a new meta-entity.
Ciocchini M; Arbelbide J; Musso CG
Int Urol Nephrol; 2017 Dec; 49(12):2171-2175. PubMed ID: 28425076
[TBL] [Abstract][Full Text] [Related]
33. A patient with persistent renal AL amyloid deposition after clinical remission by HDM/SCT therapy.
Okuyama H; Yamaya H; Fukusima T; Yokoyama H
Clin Nephrol; 2013 Mar; 79(3):233-6. PubMed ID: 23439244
[TBL] [Abstract][Full Text] [Related]
34. Myopathy in a patient with systemic AA amyloidosis possibly induced by psoriasis vulgaris: An autopsy case.
Tanabe H; Maki Y; Urabe S; Higuchi I; Obayashi K; Hokezu Y
Muscle Nerve; 2015 Dec; 52(6):1113-7. PubMed ID: 26179325
[TBL] [Abstract][Full Text] [Related]
35. IgM monoclonal gammopathy with heavy-and-light-chain amyloidosis resembling fibrillary glomerulonephritis determined by tandem mass spectrometry: a case report.
Adachi M; Kitamura M; Muta K; Maekawa A; Uramatsu T; Tadokoro M; Funakoshi S; Hisano S; Kuwahara N; Shimizu A; Mukae H; Nishino T
BMC Nephrol; 2020 May; 21(1):195. PubMed ID: 32448180
[TBL] [Abstract][Full Text] [Related]
36. Ocular manifestation of giant cell arteritis vs AL-amyloidosis: similar presentations but different approaches.
Azarfar A; Sharma A; Parikh JG; Shaikh NM; King-Morris K
Mod Rheumatol Case Rep; 2021 Jan; 5(1):117-122. PubMed ID: 32787554
[TBL] [Abstract][Full Text] [Related]
37. [Primary amyloidosis associated with IgD-lambda M-proteinemia].
Kimura S; Iwatsuka R; Aoki T; Odawara J; Asada N; Yamakura M; Takeuchi M; Matsue K
Rinsho Ketsueki; 2007 Dec; 48(12):1555-8. PubMed ID: 18203516
[TBL] [Abstract][Full Text] [Related]
38. Long-term renal survival of γ3-heavy chain deposition disease: a case report.
Katsuno T; Mizuno S; Mabuchi M; Tsuboi N; Komatsuda A; Maruyama S
BMC Nephrol; 2017 Jul; 18(1):239. PubMed ID: 28716013
[TBL] [Abstract][Full Text] [Related]
39. Nephrotic syndrome associated with generalized amyloidosis and IgM-monoclonal proteinemia.
Hirose H; Takemura Y; Honma S; Asano K; Fukui T; Satoh T; Sugiura H
Jpn J Med; 1991; 30(2):130-4. PubMed ID: 1907693
[TBL] [Abstract][Full Text] [Related]
40. The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance.
Castillo JJ; Callander NS; Baljevic M; Sborov DW; Kumar S
Am J Hematol; 2021 Jul; 96(7):846-853. PubMed ID: 33709474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
